FRAXA RESEARCH FOUNDATION
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- -
- Established
- 1994-01-01
- Employees
- -
- Market Cap
- -
- Website
- http://www.fraxa.org/
Zatolmilast Shows Promise in Treating Fragile X Syndrome
• Zatolmilast, an experimental drug, has shown potential in improving cognitive and social functions in individuals with Fragile X syndrome.
• A 2021 study indicated that zatolmilast improved memory and language skills in adult males with Fragile X over a 12-week period.
• Two ongoing larger studies are evaluating zatolmilast's efficacy, potentially leading to the first FDA-approved treatment for Fragile X syndrome.
• The drug targets an enzyme involved in memory and cognitive impairment, offering a new approach to managing Fragile X symptoms.
© Copyright 2025. All Rights Reserved by MedPath